Anti-Mouse CD1d (CD1.1) – Biotin

C57BL/6 thymocytes, RBL-CD1.1-transfected rat cell line, and CR1-CD1.1 cells

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

2 – 8° C Wet Ice

20H2 activity is directed against mouse CD1d (CD1.1) and cross reacts with CD1.2

CD1d is a non-classical major histocompatibility complex (MHC) molecule that presents glycolipid instead of peptide antigens¹ . CD1d is non-MHC-encoded, heavily glycosylated, and a surface protein associated with β2-microglobulin² . CD1d is present on invariant natural killer (iNKT) cells, where it elicits an immune response upon ligation with the T cell receptor and agonist α-galactosylceramide (α-GalCer )¹. iNKT cells activated by α-GalCer secrete cytokines and undergo proliferation. Additionally, α-GalCer can induce anti-tumor immunity. CD1d can also interact with the iNKT agonist β-mannosylceramide (β-ManCer).

20H2 was generated by immunizing male Wistar rats with C57BL/6 thymocytes, boosting three times with a RBL-CD1.1-transfected rat cell line, injecting once with BALB/c thymocytes, and finally injecting with CR1-CD1.1 cells² . The resulting spleen cells were fused with Sp2/0 cells for hybridoma production. 20H2 cross-reacts with CD1.2-transfected cells and binds to an epitope in the vicinity of the CD1d antigen-binding groove.

20H2 blocks T cell recognition of CD1d² and can be used to block β-ManCer and α-GalCer agonistic activity¹ . Blocking with 20H2 may also attenuate non-allergic asthma³ and ameliorate some aspects of neurodegenerative pathology in mouse⁴.

CD1d (CD1.1) is expressed on type I natural killer T cells also known as invariant NKT cells. CD1d is expressed by dendritic cells, macrophages, and B cells, particularly splenic marginal zone B cells.

Similar to MHC class I, associate with ß-microglobulin

1 Qin Y, Oh S, Lim S, et al. Exp Mol Med. 51(10):1-9. 2019.
2 Roark JH, Park SH, Jayawardena J, et al. J Immunol. 160(7):3121-3127. 1998.
3 Iwamura C, Nakayama T. Front Immunol. 9:1942. 2018.
4 Shin JH, Park JY, Shin YH, et al. J Immunol. 188(5):2235-2243. 2012.
5 Zeissig S, Peuker K, Iyer S, et al. Proc Natl Acad Sci U S A. 114(39):10449-10454. 2017.
6 Iba M, Kwon S, Kim C, et al. J Neuroinflammation. 21(1):93. 2024.